HIV-1 co-receptor usage and variable loop contact impacts V3 loop bnAb susceptibility.
In clinical trials, HIV-1 broadly neutralizing antibodies (bnAbs) effectively lower plasma viremia and delay virus reemergence. Presence of less neutralization susceptible strains prior to treatment decreases the efficacy of these antibody-based treatments, but neutralization sensitivity often cannot be predicted by sequence analysis alone. We find that phenotypically confirmed CXCR4- as compared to exclusive CCR5-utilizing strains are less neutralization sensitive, especially to variable loop 3 (V3) directed bnAbs in some but not all cases. Homology modeling suggests that the primary V3 loop bnAb epitope is equally accessible among CCR5- and CXCR4-using strains although variants that exclusively use CXCR4 have V3 loop protrusions that interfere with CCR5 receptor interactions. Homology modeling also shows that among some but not all envelopes with decreased neutralization sensitivity, V1 loop orientation interferes with V3 loop directed bnAb binding. Thus, there are likely different structural reasons for the co-receptor usage restriction and the differential bnAb susceptibility. Importantly, we show that individuals harboring envelopes with higher likelihood of using CXCR4 or greater predicted V1 loop interference have faster virus rebound and lower maximum decrease in plasma viremia respectively after treatment with a V3 loop bnAb. Knowledge about receptor usage and homology models may be useful in developing future algorithms that predict treatment efficacy with V3 loop bnAbs.IMPORTANCE The efficacy of HIV-1 broadly neutralizing antibody (bnAb) therapies may be compromised by the pre-existence of less susceptible variants. Sequence-based methods are needed to predict pre-treatment variants' neutralization sensitivity. HIV-1 strains that exclusively use the CXCR4 as compared to the CCR5 receptor are less neutralization susceptible, especially to variable loop 3 (V3) loop bnAbs in some but not all instances. While the inability to utilize the CCR5 receptor maps to a predicted protrusion in the envelope V3 loop, this viral determinant does not directly influence V3 loop bnAb sensitivity. Homology modeling predicts contact between the envelope V1 loop and antibody impacts V3 loop bnAb susceptibility in some cases. Among pre-treatment envelopes, increased probability of using CXCR4 and greater predicted V1 interference is associated with faster virus rebound and lower decrease in plasma virus level respectively after V3 loop bnAb treatment. Receptor usage information and homology models may be useful for predicting V3 loop bnAb therapy efficacy.